RxDoctor Payments Data

Brett Earnest, MD

Family Medicine · New Braunfels, TXNPI 1134389711

Payments from drug & device makers

$2,503in general payments, 2019–2025

Across 124 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$716
  • Lilly USA, LLC$505
  • Novo Nordisk$144
  • Collegium Pharmaceutical, Inc.$139
  • Ironshore Pharmaceuticals Inc.$134
  • Merck$105
  • plus $760 from 18 others

What the payments were for

  • Food & beverage$2,40396%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,503 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$52,078
Medicare patients
140
Services billed
751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol57$53,079
JardianceEmpagliflozin52$35,584
EliquisApixaban35$29,631
XareltoRivaroxaban21$25,791
MounjaroTirzepatide25$25,252
OzempicSemaglutide20$22,304
TrulicityDulaglutide16$20,887
JanuviaSitagliptin Phosphate15$20,329
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$19,731
QuliptaAtogepant13$13,973
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,980
Janumet XrSitagliptin Phos/Metformin Hcl12$2,428
Testosterone15$2,266
Levothyroxine Sodium142$1,911
Atorvastatin Calcium249$1,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$42$72,81081 claims
Lilly USA, LLCMounjaro, Trulicity$505$46,13841 claims
PfizerEliquis$26$29,63135 claims
MerckJanuvia, Janumet Xr$105$22,75727 claims
Novo NordiskOzempic$144$22,30420 claims
AbbVieQulipta, Synthroid$716$14,75330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in New Braunfels

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →